Relationship Between Self-compassion and Treatment Adherence in Schizophrenic Spectrum Disorders

NCT ID: NCT05566015

Last Updated: 2023-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-26

Study Completion Date

2023-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment adherence is defined by the World Health Organisation (WHO) as the extent to which the patient's history of therapeutic drug-taking coincides with the prescribed treatment. In patients suffering from psychiatrical diseases, especially in those who are suffering from schizophrenic spectrum disorders, the quality of treatment adherence has to be improved. Indeed, non adherance to anti-psychotic treatment increases the risk of hospitalization, of substance use, violent behaviour and of functionnal and cognitif impairment. Selfcompassion, which involves being touched by and open to one's own suffering and to heal oneself with kindness and without judgement and self-criticism has never beed studied as a possible factor infuencing treatment adherence.

This study aims to evaluate if a link between selfcompassion and treatment adherence exists in patients suffering from schizophrenic spectrum disorders.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Treatment Adherence Selfcompassion Schizophrenic Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

questionnaire

self-administered questionnaires as well as clinical assessment of schizophrenia symptoms and depression.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with schizophrenia spectrum disorder ( ICD 10 and DSM 5 criteria)
* stabilized (PANNS score under 80)
* aged 18 or above
* In case of tutor or curator, agreement of this person is requiered
* psychiatrist who's following the patient agrees with the study

Exclusion Criteria

* underage
* non stabilized patient (PANSS score under 80 )
* patient suffering from toxic psychosis
* difficulties to understand french or cognitive impairment which are making it to difficult to answer the different self-administered questionnaires.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Crysalid center Clermont de l'Oise

UNKNOWN

Sponsor Role collaborator

CMP de Montataire

UNKNOWN

Sponsor Role collaborator

CMP de Chambly

UNKNOWN

Sponsor Role collaborator

CMP de Clermont de l'Oise

UNKNOWN

Sponsor Role collaborator

CMP de st Just en Chaussée

UNKNOWN

Sponsor Role collaborator

CMP de Senlis

UNKNOWN

Sponsor Role collaborator

CMP de Crepy en Valois

UNKNOWN

Sponsor Role collaborator

CMP de Pont St Maxence

UNKNOWN

Sponsor Role collaborator

CMP de Chantilly

UNKNOWN

Sponsor Role collaborator

CMP de Creil

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Universitaire, Amiens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Amiens

Amiens, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI2019_843_0021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Intervention Psychosis and Addiction
NCT01411566 UNKNOWN EARLY_PHASE1